In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

European Journal of Heart Failure

Advancing knowledge in the field of heart failure management

 

The European Journal of Heart Failure (EJHF) is dedicated to the advancement of knowledge in the field of heart failure management.

The journal publishes reviews and editorials to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as clinical, social and population sciences all form part of the discipline.

Submit your paper

Fast Facts

  • Editor-in-chief: Michael Böhm (DE)
  • Current volume: 26 (year 2024)
  • Issues per subscription: 12
  • Impact Factor 2022:  18.2

Editor-in-chief History

Name Start Date End Date
Professor John Cleland 01/01/1999 31/12/2004
Professor Karl Swedberg 01/01/2005 31/12/2009
Professor Dirk J. Van Veldhuisen 01/01/2010 31/12/2014
Professor Marco Metra 01/01/2015 31/03/2024
Professor Michael Böhm 01/04/2024  
Updates on latest articles

Updates on latest articles

 

Receive the table of contents in your mailbox.

Track topics and authors important to you and receive articles in your mailbox.

For Authors

Before being published, all manuscripts go through double-blind peer review by experienced international experts.


Most recent articles from EJHF

27 May 2024
Is the optimal dose of heart failure medical therapy different in women and men?
Author(s): Maria A. Pabon, Muthiah Vaduganathan, Carolyn S.P. Lam
24 May 2024
Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial
Author(s): Carolyn S.P. Lam, Lars Køber, Koichiro Kuwahara, Lars H. Lund, Patrick B. Mark, Linda G. Mellbin, Morten Schou, Patricia Ely Pizzato, Anders Gabrielsen, Samvel B. Gasparyan, Alessandro Ghiretti, Judith Hartleib‐Geschwindner, Greggory J. Housler, Paolo Fanti, Maria Leonsson‐Zachrisson, John J.V. McMurray, Scott D. Solomon, for the MIRACLE Study Investigators
27 May 2024
Sacubitril/valsartan for the treatment of non‐obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM)
Author(s): Lazar Velicki, Dejana Popovic, Nduka C. Okwose, Andrej Preveden, Milorad Tesic, Maria Tafelmeier, Sarah J. Charman, Fausto Barlocco, Guy A. MacGowan, Petar M. Seferovic, Nenad Filipovic, Arsen Ristic, Iacopo Olivotto, Lars S. Maier, Djordje G. Jakovljevic, SILICOFCM Investigators
24 May 2024
Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESC
Author(s): Giuseppe M.C. Rosano, Davide Stolfo, Lisa Anderson, Magdy Abdelhamid, Marianna Adamo, Johann Bauersachs, Antoni Bayes‐Genis, Michael Böhm, Ovidiu Chioncel, Gerasimos Filippatos, Loreena Hill, Mitja Lainscak, Ekaterini Lambrinou, Angela H.E.M. Maas, Angela R. Massouh, Brenda Moura, Mark C. Petrie, Amina Rakisheva, Robin Ray, Gianluigi Savarese, Hadi Skouri, Sophie Van Linthout, Cristiana Vitale, Maurizio Volterrani, Marco Metra, Andrew J.S. Coats